Analyst Price Target is GBX 325
▲ +0.87% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Indivior in the last 3 months. The average price target is GBX 325, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a 0.87% upside from the last price of GBX 322.20.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Indivior. This Buy consensus rating has held steady for over two years.
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.